Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-10T06:46:38.427Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics

Published online by Cambridge University Press:  09 July 2009

Timothy G. Dinan
Timothy G. Dinan*
Affiliation:
Department of Psychological Medicine, St. Bartholomew's Hospital, London
*
1Address for correspondence: Dr. T. G. Dinan, Department of Psychological Medicine, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Platelet-rich plasma from healthy controls was pre-treated with neuroleptics of the phenothiazine, butyrophenone or benzamide variety before aggregation with one of the following agonist agents: ADP, adrenaline, 5-HT, collagen, platelet activating factor or ristocetin. All compounds effective as antipsychotics, except sulpiride, depressed aggregation. Unmedicated schizophrenics showed aggregation responses indistinguishable from healthy controls. However, within days of treatment with either trifluoroperazine or haloperidol responses became abnormal in acutely psychotic patients. Increased responses to 5-HT and depressed responses to platelet activating factor were detected. After 4 weeks of treatment responses tended to return to normal. Aggregation responses were normal in those patients on long-term depot neuroleptics.

Type
Research Article
Information
Psychological Medicine , Volume 17 , Issue 4 , November 1987 , pp. 875 - 881
Copyright
Copyright © Cambridge University Press 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abdulla, Y. H. & Hamadah, K. (1975). Effect of ADP on PGE1 formation in blood platelets from patients with depression, mania and schizophrenia. British Journal of Psychiatry 127, 591–596.CrossRefGoogle ScholarPubMed
American Psychiatric Association, (1980). Diagnostic and Statistical Manual of Mental Disorders-111. American Psychiatric Association: Washington.Google Scholar
Baumgartner, H. R. & Born, G. V. R. (1968). Effects of 5-hydroxytryptamine on platelet aggregation. Nature 218, 137–141.CrossRefGoogle ScholarPubMed
Boullin, D. J., Grahame-Smith, D. G., Grimes, R. P. J. & Woods, H. F. (1975 a) Inhibition of 5-hydroxytryptamine induced human blood platelet aggregation by chlorpromazine and its metabolites. British Journal of Pharmacology 53, 121–129.CrossRefGoogle ScholarPubMed
Boullin, D. J., Woods, H. F., Grimes, R. P. J., Grahame-Smith, D. G., Wiles, D., Gelder, M. G. & Kolakowska, T. (1972 b) Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. British Journal of Clinical Pharmacology 2, 29–35.CrossRefGoogle Scholar
Boullin, D. J. & Genton, A. M. (1978). Characterization of receptors mediating 5-hydroxytryptamine and catecholamine induced platelet aggregation, assessed by the actions of α- and β-blockers, butyrophenones, 5-HT antagonists and chlorpromazine. British Journal of Pharmacology 62, 537–542.CrossRefGoogle ScholarPubMed
Campbell, I. C. (1981). Blood platelets and psychiatry. British Journal of Psychiatry 138, 78–80.CrossRefGoogle ScholarPubMed
Edwards, J., Alexander, J. R., Alexander, M. S., Gordon, A. & Zutchi, T.Controlled trial of sulpiride in chronic schizophrenic patients. British Journal of Psychiatry 137, 522–529.CrossRefGoogle Scholar
Feinstein, M. B. & Hadjian, R. A. (1982). Effects of the calmodulin antagonist trifluoperazine on stimulus-induced calcium mobilization, aggregation, secretion and protein phosphorylation in platelet. Molecular Pharmacology 21, 422–431.Google Scholar
Gould, R. R., Murphy, K. M., Reynold, I. J. & Snyder, S. W. (1983). Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proceedings of the National Academy of Sciences (USA) 80, 5122–5125.CrossRefGoogle ScholarPubMed
Ishigooka, J., Tanaka, K., Suzuki, Y., Katori, M. & Miura, S. (1980). Selective inhibitory effects of chlorpromazine and imipramine in platelet aggregation. International Pharmacopsychiatry 15, 270–280.CrossRefGoogle ScholarPubMed
Kaiya, J. M., Imai, H., Muramatsu, Y., Nozaki, M., Fujimura, H., Adachi, S. & Namba, M. (1983). Platelet aggregation response in schizophrenia and prostaglandin El. Psychiatric Research 9, 309–318.CrossRefGoogle Scholar
Knox, J. M., Orr, M. W, Allen, R., Gelder, M. G. & Grahame-Smith, D. G. (1981). The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs. British Journal of Clinical Pharmacology 11, 261–263.CrossRefGoogle ScholarPubMed
Levin, R. M. & Weiss, B. (1977). Binding of trifluoperazine to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. Molecular Pharmacology 13, 690–697.Google Scholar
Levy, J. V. (1983 a). Calmodulin antagonist W-7 inhibits human platelets induced by platelet activating factor. Proceedings of the Society for Experimental Biological Medicine 172, 293–295.CrossRefGoogle ScholarPubMed
Levy, J. V. (1983 b). Calmodulin anatagonists inhibit aggregation of human, guinea pig and rabbit platelets induced with platelet activating factor. Febs Letters 154, 262–264.CrossRefGoogle Scholar
Mills, D. C. B. & Roberts, G. C. K. (1967). Membrane active drugs and the aggregation of human blood platelets. Nature 213, 35–38.CrossRefGoogle Scholar
Orr, M. W. & Boullin, D. J. (1976). The relationship between changes in 5-HT induced aggregation and clinical state in patients treated with fluphenazine. British Journal of Clinical Pharmacology 3, 925–928.CrossRefGoogle Scholar
Orr, M. W., Knox, J. M., Allen, R., Gelder, M. G. & Grahame-Smith, D. G. (1981). The effect of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. British Journal of Clinical Pharmacology 11, 255–259.CrossRefGoogle ScholarPubMed
Romstedt, K. & Akbar, H. (1985). Benzodiazepines inhibit platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam. Thrombosis Research 38, 361–374.CrossRefGoogle ScholarPubMed
Shaw, J. O. & Henson, P. M. (1980). The binding of rabbit basophilderived platelet activating factor to rabbit platelets. American Journal of Pathology 98, 791–810.Google ScholarPubMed
Stahl, S. (1977). The human platelet. Archives of General Psychiatry 34, 509–516.CrossRefGoogle ScholarPubMed
Whalley, L. J., Reading, H. W. & Rosie, R. (1984). ADP and arachidonic acid induced platelet aggregation in schizophrenia and atypical psychosis. Psychological Medicine 14, 207–211.CrossRefGoogle Scholar
Wing, J. K., Cooper, J. E. & Sartorius, N. (1974) The Measurement and Classification of Psychiatric Symptoms. Cambridge University Press: Cambridge.Google Scholar
Youdim, M. B. H., Hefez, A. & Oppenheim, B. (1981). Human platelet function as a model for investigating the clinical efficacy of chlorpromazine. British Journal of Clinical Pharmacology 12, 535–542.CrossRefGoogle Scholar
Zucker, M. B. (1980). The functioning of blood platelets. Scientific American 242, 86–103.CrossRefGoogle ScholarPubMed